Gastric Emptying

Biomarker

Related News

Pfizer Starts Phase 1 Study of PF-08653944 in Adults With Overweight or Obesity

May 17, 2026

Pfizer is running a Phase 1 open-label multiple-dose study of PF-08653944 in adults with overweight or obesity. The study will assess gastric emptying and safety, with an update filed on 20 April 2026.

Semaglutide and Other GLP-1 Peptides Show Significant Weight Loss Results in Clinical Studies

Feb 17, 2026

Semaglutide and other GLP-1 receptor agonists demonstrate substantial weight loss effectiveness through appetite regulation and blood sugar control, with clinical studies showing average reductions of 14.9% to 20.9% body weight.